Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

ClinicalTrials.gov ID: NCT00098722

Public ClinicalTrials.gov record NCT00098722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects

Study identification

NCT ID
NCT00098722
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
ViiV Healthcare
Industry
Enrollment
474 participants

Conditions and interventions

Conditions

Interventions

  • Maraviroc (UK-427,857) Drug
  • optimized background therapy Drug

Drug

Eligibility (public fields only)

Age range
16 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2004
Primary completion
Mar 31, 2007
Completion
Mar 31, 2011
Last update posted
May 15, 2012

2004 – 2011

United States locations

U.S. sites
62
U.S. states
20
U.S. cities
47
Facility City State ZIP Site status
Pfizer Investigational Site Hobson City Alabama 36201
Pfizer Investigational Site Garden Grove California 92845
Pfizer Investigational Site Los Angeles California 90036
Pfizer Investigational Site Oakland California 94609-3480
Pfizer Investigational Site Palm Springs California 92262
Pfizer Investigational Site Tarzana California 91356
Pfizer Investigational Site Norwalk Connecticut 06851
Pfizer Investigational Site Southport Connecticut 06490
Pfizer Investigational Site Stratford Connecticut 06614
Pfizer Investigational Site Washington D.C. District of Columbia 20007
Pfizer Investigational Site Washington D.C. District of Columbia 20010-2976
Pfizer Investigational Site Clearwater Florida 33765
Pfizer Investigational Site Hollywood Florida 33021-6327
Pfizer Investigational Site Miami Florida 33137
Pfizer Investigational Site Miami Florida 33145
Pfizer Investigational Site Miami Florida 33155
Pfizer Investigational Site Miami Beach Florida 33139
Pfizer Investigational Site Pensacola Florida 32504
Pfizer Investigational Site Safety Harbor Florida 34695
Pfizer Investigational Site St. Petersburg Florida 33713
Pfizer Investigational Site Tampa Florida 33611
Pfizer Investigational Site Tampa Florida 33614
Pfizer Investigational Site Atlanta Georgia 30309
Pfizer Investigational Site Atlanta Georgia 30318-2513
Pfizer Investigational Site Atlanta Georgia 30339-3915
Pfizer Investigational Site Jonesboro Georgia 30236
Pfizer Investigational Site Chicago Illinois 60613
Pfizer Investigational Site Chicago Illinois 60657
Pfizer Investigational Site Springfield Illinois 62702
Pfizer Investigational Site Metairie Louisiana 70006
Pfizer Investigational Site Baltimore Maryland 21201
Pfizer Investigational Site Silver Spring Maryland 20910
Pfizer Investigational Site Ann Arbor Michigan 48109-0008
Pfizer Investigational Site Ann Arbor Michigan 48109-0352
Pfizer Investigational Site Detroit Michigan 48201
Pfizer Investigational Site Detroit Michigan 48202
Pfizer Investigational Site Kansas City Missouri 64106
Pfizer Investigational Site St Louis Missouri 63139-2909
Pfizer Investigational Site Buffalo New York 14215
Pfizer Investigational Site East Meadow New York 11554
Pfizer Investigational Site Elmira New York 14905
Pfizer Investigational Site New York New York 10011
Pfizer Investigational Site New York New York 10016
Pfizer Investigational Site New York New York 10025
Pfizer Investigational Site New York New York 10029
Pfizer Investigational Site Greenville North Carolina 27834
Pfizer Investigational Site Akron Ohio 44304
Pfizer Investigational Site Cleveland Ohio 44109
Pfizer Investigational Site Tulsa Oklahoma 74135
Pfizer Investigational Site Portland Oregon 97210
Pfizer Investigational Site Portland Oregon 97227
Pfizer Investigational Site West Reading Pennsylvania 19611
Pfizer Investigational Site Charleston South Carolina 29403
Pfizer Investigational Site Charleston South Carolina 29425
Pfizer Investigational Site Dallas Texas 75219
Pfizer Investigational Site Fort Worth Texas 76104
Pfizer Investigational Site Fort Worth Texas 76107
Pfizer Investigational Site Pasadena Texas 77505-4245
Pfizer Investigational Site Danville Virginia 24541
Pfizer Investigational Site Hampton Virginia 23666
Pfizer Investigational Site Lynchburg Virginia 24501
Pfizer Investigational Site Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 110 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00098722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 15, 2012 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00098722 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →